康艾注射液联合放疗治疗非小细胞肺癌随机平行对照研究

目的]观察康艾注射液联合放疗治疗非小细胞肺癌疗效。方法]使用随机平行对照方法,将76例住院患者按住院病志号简单随机分为两组。对照组34例常规放射治疗,射野包括原发灶、同侧肺门、纵膈隆突下淋巴结、引流区,若病灶单一,且位于边缘,则照射病灶区及病灶外扩1.0~1.5cm区域,有明显淋巴结肿大区域,也包括在射野内6mv-X射线2ay/f DT36gy后射野避开脊髓,总剂量DT60GY~70GY。治疗组42例康艾注射液10 mL/支,40~60 mL+0.9%生理盐水,静滴,1次/d;放疗同对照组。治疗30d为1疗程。观测临床症状、T淋巴细胞亚群(CD+3 CD+4 CD+8 CD+4/CD+8)、卡式评分、不良反应(白细胞降低,体重下降,乏力改善以及伴发症状疼痛、低热、胸闷、食欲不振等)。治疗1疗程,随访四周,判定疗效。结果]瘤体消退治疗组优于对照组(P0.05);相关指标(体重、白细胞、乏力、生活质量,疼痛、低热、胸闷、食欲不振)治疗组改善优于对照组(P0.05),生活质量,疼痛、低热、胸闷、食欲不振等改善两组间无明显差异(P0.05);卡氏评分对照组明显降低(P0.05),治疗组无明显变化(P0.05),治疗组降低幅度低于对照组(P0.05);T细胞亚群(CD+3CD+4 CD+8 CD+4/CD+8)治疗组无明显变化(P0.05),对照组明显降低(P0.01),对照组优于治疗组(P0.01)。结论]康艾注射液联合放疗治疗非小细胞肺癌,可明确减轻毒副作用、缓解不适症状、改善生活质量,疗效满意,值得推广。

Non Small Cell Lung Cancer Study Random Parallel Control of Kangai Injection Combined with Radiotherapy

Objective] Observe Kang＇ai injection combined with radiotherapy for non-small cell lung cancer. Method] Random parallel control method, 76 cases of hospitalized patients were hospitalized patients were randomly divided into two groups Zhi number, 42 cases of the treatment group and the control group of 34 patients, conventional radiation therapy, radiation field included the primary tumor, ipsilateral hilar, subcarinal mediastinal lymph nodes under the drainage area, if a single lesion, and is located at the edge, then irradiated lesions and lesions 1.0 -1.5cm expand outside the region, there are significant regional lymph nodes, also included in the radiation field within 6my-X-ray 2ay / f DT36gy avoid spinal radiation field after a total dose DT6OGY - 70GY. Treatment group 00 cases Kang＇ai injection 10 mL / branch, 40 - 60 mL ＋0.9% saline infusion, 1 / d;radiotherapy with the control group. 30d is a continuous course of treatment. Observation of clinical symptoms, T lymphocyte subsets （ CD ＋3 CD ＋4 CD ＋8 CD ＋4 / CD ＋8 ）, score card, adverse reactions （ leukopenia, weight loss, fatigue, and improve symptoms associated with pain, fever, lightheadedness, loss of appetite, etc. ） . 00 continuous treatment regimen to determine efficacy. Results ] Tumor regression therapy group than the control group （P〈0.05） ;relevant indicators （ body weight, white blood cells, fatigue, quality of life, pain, fever, chest tightness, loss of appetite ） to improve the treatment group than the control group （ P〈0.05 ）, quality of life, pain, fever, chest tightness, loss of appetite, no significant difference in improvement between the two groups （P〉 0.05 ） ;Karnofsky score decreased significantly in both groups / increased （ P 〈0.05 ）, the treatment group decreased / increased than the control group （ P 〈0.05 ） / no significant difference between the two groups （ P〉 0.05 ） ;T cell subsets （ CD ＋3 CD ＋4 CD ＋8 CD ＋4 / CD ＋8 ） no significant change in the